Drug Trial Radar · NCT06468228
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,400
Actual
Start
Jun 27, 2024
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jun 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. This study will compare lutikizumab versus placebo for the treatment of adult and adolescent participants with the signs and symptoms of moderate to severe HS . Lutikizumab is an investigational drug being developed for the treatment of HS. During Period 1 of the study, participants will placed in 1 of 2 groups called treatment arms. There is a 1 in 2 chance that participants will be assigned to placebo. Around 1280 adult and adolescent participants with moderate to severe HS will be enrolled in the study at approximately 275 sites world wide. During Period 2, participants that were part of the lutikizumab treatment arm in Period 1 will be re-randomized to 1 of 2 lutikizumab treatment arms. Participants that were part of the Placebo arm in Period 1 will start Period 2 with an initiation of lutikizumab followed by a re-randomization to 1 of 2 lutikizumab treatment arms. In Period 1, participants will receive subcutaneous injections of lutikizumab or placebo every week for 16 weeks. In Period 2, participants that were randomized to lutikizumab in Period 1 will receive subcutaneous injections of lutikizumab every week or every other week for 36-weeks. Participants that were randomized to the placebo arm in Period 1 will receive subcutaneous injections of lutikizumab every week for 16 weeks, then either every week or every other week for 20 weeks. Period 3 is the Long Term Extentsion (LTE) and through Week 68, participants will continue to receive lutikizumab SC using the same assigned dosing regimen from the end of Period 2 for 16 weeks followed by open-label lutikizumab EOW for 140 weeks. Participants in the US that complete Periods 1 \& 2 will have the option to enroll in a 156-week open-label Sub-Study that will assess the long term safety and efficacy of lutikizumab in a prefilled pen. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires and diaries.
Conditions
- Hidradenitis Suppurativa
Interventions
LutikizumabDrug
Subcutaneous injection
PlaceboDrug
Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR) 75Time frame: At Week 16
- Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately Week 62
Locations
279 sites in 44 countries. Site status is shown where the registry gives one.
Cahaba Dermatology & Skin Health Center /ID# 263795
Birmingham, Alabama
Medical Dermatology Specialists /ID# 263394
Phoenix, Arizona
Banner University Medicine Dermatology /ID# 263557
Tucson, Arizona
Dermatology Trial Associates /ID# 264587
Bryant, Arkansas
Arkansas Research Trials /ID# 263901
North Little Rock, Arkansas
Private Practice - Dr. Tooraj Raoof /ID# 263756
Encino, California
Dermatology Research Associates - Los Angeles /ID# 263765
Los Angeles, California
Stanford University School of Medicine - Redwood City /ID# 263711
Redwood City, California
Norcal Clinical Research /ID# 279008
Rocklin, California
Integrative Skin Science and Research /ID# 264600
Sacramento, California
Clinical Trials Research Institute /ID# 263743
Thousand Oaks, California
Yale University School of Medicine /ID# 263695
New Haven, Connecticut
Clearlyderm Dermatology - West Boca /ID# 265023
Boca Raton, Florida
Apex Clinical Trials /ID# 263815
Brandon, Florida
TrueBlue Clinical Research - Brandon /ID# 265041
Brandon, Florida
Florida Academic Dermatology Center /ID# 263834
Coral Gables, Florida
Direct Helpers Research Center /ID# 278343
Hialeah, Florida
Skin Care Research - Hollywood /ID# 263805
Hollywood, Florida
Gsi Clinical Research /ID# 263827
Margate, Florida
Sullivan Dermatology /ID# 263511
Miami, Florida
Vitalia Medical Research /ID# 278321
North Palm Beach, Florida
Renstar Medical Research - Ocala - Northeast 1st Avenue /ID# 263842
Ocala, Florida
Skin Care Research - Tampa /ID# 263819
Tampa, Florida
Advanced Clinical Research Institute - Tampa /ID# 263808
Tampa, Florida
University of South Florida /ID# 269624
Tampa, Florida
Alliance Clinical Research of Tampa /ID# 264594
Tampa, Florida
TruDerm Research /ID# 278217
Wellington, Florida
Centricity Research Columbus Dermatology /ID# 266530
Columbus, Georgia
Cleaver Medical Group Dermatology /ID# 263845
Dawsonville, Georgia
Treasure Valley Medical Research /ID# 263671
Boise, Idaho
DeNova Research /ID# 264593
Chicago, Illinois
Northwestern University Feinberg School of Medicine /ID# 265007
Chicago, Illinois
Arlington Dermatology /ID# 263410
Rolling Meadows, Illinois
Dawes Fretzin /ID# 264601
Indianapolis, Indiana
Dermatology Partners of Leawood /ID# 263533
Leawood, Kansas
Equity Medical, LLC /ID# 268590
Bowling Green, Kentucky
Dermatology Specialists Research (DS Research) - Kentucky /ID# 263343
Louisville, Kentucky
Tulane University School of Medicine /ID# 263899
New Orleans, Louisiana
Beth Israel Deaconess Medical Center /ID# 263709
Boston, Massachusetts
UMass Memorial Medical Center - Lake Avenue North /ID# 274149
Worcester, Massachusetts
Showing 40 of 279 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.